2017 News

DNAtrix Virus Expressing T-Cell Co-stimulator OX40L (CD252) Presented at the 2017 Society for Immunotherapy of Cancer Meeting

Houston, TX – November 13, 2017 – Juan Fueyo, MD, Professor at MD Anderson Cancer Center Department of Neuro-Oncology, presented results of a comprehensive study on the oncolytic virus Delta-24-RGDOX at the 2017 Society for Immunotherapy of Cancer (SITC) Meeting, held in National Harbor, MD on November 10th – 12th.

DNAtrix, an oncolytic virus company, is developing Delta-24-RGDOX (also known as DNX-2440), which locally expresses OX40L (CD252) in tumor cells following infection. The Delta-24-RGDOX backbone is based on the highly potent oncolytic adenovirus, DNX-2401, currently in Phase 2 testing with Merck’s checkpoint inhibitor, Keytruda. The data presented at SITC builds on Dr. Fueyo’s recent publication in Cancer Research, and demonstrates that Delta-24-RGDOX triggers an antitumor immune response, an abscopal effect, and tumor-specific immune memory, leading to prolonged survival in difficult-to-treat models of cancer.

“DNAtrix is developing best-in-class oncolytic viruses that replicate and persist for weeks to aggressively kill tumor cells while triggering an acute immune response.  Delta-24-RGDOX is an excellent example of DNAtrix’s platform, as it delivers effective combination therapy for cancers while minimizing side effects and cost,” said Frank Tufaro, PhD, CEO of DNAtrix. “We have already shown that DNAtrix oncolytic viruses can be combined safely with other chemotherapies and immunotherapies to provide a new modality for treating cancers.” 

Details of the presentation:

Efficacious Anti-Melanoma Immunity Induced by OX40 Ligand-Expressing Oncolytic Adenovirus Delta-24-RGDOX

Abstract Number: P409

Presenter: Hong Jiang, PhD

To access the recently published paper on Delta-24-RGDOX, visit the Cancer Research website http://cancerres.aacrjournals.org/content/77/14/3894.long

For more information about ongoing DNAtrix clinical studies, visit the website ClinicalTrials.gov: NCT02798406 (DNX-2401 + KEYTRUDA for recurrent glioblastoma) and NCT03178032 (DNX-2401 monotherapy for newly diagnosed pediatric diffuse intrinsic pontine glioma). 

About DNAtrix Armed Virus Platform

DNAtrix is developing oncolytic viruses that feature the backbone of DNX-2401 and express immune modulatory molecules following infection of tumor cells. The first candidates, expressing members of the TNF receptor superfamily that enhance T-cell activity, have shown remarkable efficacy in animal models of cancer, including breast, melanoma, brain and lung.  The first virus on this platform, DNX-2440, which expresses OX40 ligand, will enter the clinic soon for evaluation in a variety of solid tumors.

About DNAtrix

DNAtrix is a privately held, clinical stage, biopharmaceutical company developing oncolytic virus immunotherapies for cancer. DNAtrix’s lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT).  For more information, please visit the company website at http://www.DNAtrix.com.


Imran Alibhai, PhD
SVP Business Development